Skip to main
TEM

TEM Stock Forecast & Price Target

TEM Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 42%
Buy 25%
Hold 25%
Sell 8%
Strong Sell 0%

Bulls say

Tempus AI Inc demonstrates a positive outlook based on its notable revenue growth and strong market positioning within the healthcare technology sector. The company reported total revenue growth of 84.7% year-over-year, driven primarily by a remarkable 117.2% increase in Genomics revenue to $252.9 million, alongside a 26.1% rise in Data & Other revenue. Furthermore, expectations for higher average selling prices (ASPs) from its xF liquid biopsy assay and a shift to its xT CDx test indicate a promising trajectory for continued expansion and profitability in the coming quarters.

Bears say

Tempus AI Inc has seen a notable decline in gross margins within its Data & Other segment, falling from 76.8% in Q3 of the previous year to 69.7% in the most recent quarter, indicating potential challenges in maintaining profitability. The company continues to incur significant losses and has a sizable debt load of $518.8 million against cash reserves of $764.3 million, raising concerns about its financial sustainability and ability to achieve positive operating cash flow, which decreased by $168.5 million year-over-year. Additionally, there are substantial risks related to slower-than-expected sales growth, regulatory hurdles, and customer retention, all contributing to an overall negative outlook for Tempus AI's future performance.

TEM has been analyzed by 12 analysts, with a consensus rating of Buy. 42% of analysts recommend a Strong Buy, 25% recommend Buy, 25% suggest Holding, 8% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Tempus AI Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Tempus AI Inc (TEM) Forecast

Analysts have given TEM a Buy based on their latest research and market trends.

According to 12 analysts, TEM has a Buy consensus rating as of Apr 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $72.83, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $72.83, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Tempus AI Inc (TEM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.